Invest now
Mercury Laboratories share price
High risk
You have to be logged in to add this to Watchlist.- ₹751.00(-0.29%)September 3, 2026 15:50:00 PM IST
- NSE
- BSE
- Vol : 0.01 K (NSE + BSE)Last 20 day avg : 0.09 K
Mercury Laboratories is trading -0.29% lower at Rs 751.00 as compared to its last closing price. Mercury Laboratories has been trading in the price range of 770.00 & 751.00. Mercury Laboratories has given -7.42% in this year & -3.84% in the last 5 days. The company posted a net profit of 0.30 Crores in its last quarter.Listed peers of Mercury Laboratories include Sun Pharmaceutical Industries (-0.26%), Divi's Laboratories (-1.57%), Torrent Pharmaceuticals (-1.52%).The Mutual Fund holding in Mercury Laboratories was at -% in . The MF holding has - from the last quarter. The FII holding in Mercury Laboratories was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 06 Sep 2026, 06:02 AM IST
- BetaMedium volatility1.06Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Dividend YieldLower than industry0.47Annual dividends as a percentage of the stock price.
- P/BLower than historical values1.55The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values21.65Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates undervaluation-4.64The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- Debt To Equity-The debt-to-equity ratio, indicating a company's financial leverage.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Mercury Laboratories Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,899.00 | -0.26 | 4,55,622.97 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 9,100.00 | -1.57 | 2,41,576.41 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,850.00 | -1.52 | 1,84,478.41 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,385.00 | -0.29 | 1,11,887.66 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,121.00 | -1.23 | 1,11,820.17 | 21.19 | 4.24 | 0.09 | 14.22 |
Mercury Laboratories Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-07-25 | Quarterly Results |
| 2026-05-29 | Audited Results & Final Dividend |
| 2026-02-11 | Quarterly Results |
| 2025-11-11 | Quarterly Results |
| 2025-08-13 | Quarterly Results |
About the company Mercury Laboratories
- IndustryBiotechnology & Drugs
- ISININE947G01011
- BSE Code538964
- NSE Code
Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. It is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, and innovative products. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.
Mercury Laboratories Share Price FAQs
Mercury Laboratories is trading at 751.00 as on Thu Sep 03 2026 10:20:00. This is -0.29% lower as compared to its previous closing price of 751.00.
The market capitalization of Mercury Laboratories is 90.12 Cr as on Thu Sep 03 2026 10:20:00.
The 52 wk high for Mercury Laboratories is 942.90 whereas the 52 wk low is 620.55
Mercury Laboratories can be analyzed on the following key metrics -
- TTM P/E: 22.68
- Sector P/E: -
- Dividend Yield: 0.47%
- D/E ratio: -
Mercury Laboratories reported a net profit of 4.83 Cr in 2026.
Quick Links
EQUITY QUICK LINKS
Mercury Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.